



Value Added Drugs Corporate Presentation

2022

HISTORY AND MILESTONES



2011

- Spin Off from Parent Company Ethypharm and renamed ATHENADDs

2012

- ATHENA DDS India 🇮🇳 EUGMP approval for ODT & Tablets

2014

- ATHENA Shanghai R&D JV China 🇨🇳

2015

- Registrations : EU4, UK2, CA 1, RUS2, SA1 & others 6 (total 16)

2017

- ATHENA DDS India 🇮🇳 EUGMP extension to capsules & sachets

2018

- Registrations : EU2, UK1, CA 1, Mexico 1, others 8 (total 13)
- ATHENA DDS India 🇮🇳 GMP accreditation from Health Canada 🇨🇦 and SAHPRA- South Africa 🇿🇦

2019

- ATHENA DDS India 🇮🇳 GMP accreditation from ANVISA - Brazil 🇧🇷, Ministry of Health Russia - Federation - Russia 🇷🇺, TGA - Australia 🇦🇺
- Opening ATHENABRAZIL 🇧🇷

2020

- Acquisition of Rottendorf Inpharmasci factory France, renamed ATHENA IPS France 🇫🇷
- Effervescent tablets and sticks investment in ATHENA IPS
- Opening ATHENA Canada 🇨🇦 Office

2021

- Launch of ATHENA Pharmaceutique's 1st product in France 🇫🇷

TEAM



Alexandre Williams
President



Maryline Boyer
Scientific Director

ATHENA DDS India



Mahendra Chaudhari
Site Manager India



Vidya More
VP QA India



Subhash Kumar
CFO India



Hedge Vishwanath
VP Project / Regulatory India



Amit Patil
Head Business India



Minal Kamat
Human Resources India



ATHENA IPS France



Fabienne Riaucourt
Site Manager France



François Bellefeuille
QA Manager France



Philippe Nabais
CFO France



Guillaume Herier
Head Business France



Jessica Gilles
Human Resources France

ATHENA Canada



Hafid Touam
VP North America

ATHENA Brazil



Bruno Schauenberg
Brazil

ATHENA China

STRUCTURE

engineering possibilities



ATHENA
PHARMACEUTIQUES



2011

Athena Pharmaceutiques
S.A.S own patents, dossiers



2011



2012



2019



2020



2021

ATHENA DDS
PLANT INDIA.
100 %

ATHENA
R&D JV SHANGAI
55 %

ATHENA BRAZIL
COMMERCIAL OFFICE
100 %

INPHARMASI
S.A.S PLANT FRANCE
100 %

ATHENA CANADA
COMMERCIAL OFFICE
100 %



PLANT AND R&D FACILITY



- Licensing and supply
- Co-Developments
- CTD products to be marketed under Partner's Brand
- Supply in Semi Finished Bulk or Finished Packs
- Full Service CDMO

**400 people dedicated to
differentiated branded generic**



Full service CDMO for Generic
and Specialty Pharma
150 people in FRANCE Valenciennes



Development
and Manufacturing
250 people in INDIA Mumbai

COLLABORATION MODEL



TARGET PRODUCTS ARE LIFECYCLE & HYBRIDS IN ORAL SOLID

- Modified Release or taste masked products
- Humidity relative products (Soluble/Effervescent...)
- Corticoids (Prednisolone/Hydrocortisone/Fludrocortisone)
- Narcotic (Codeine, Oxycodone, Morphine...)
- OTC with special technology (effervescent tablets and stick/ODT...)
- Orphan

ATHENA take full responsibility for the DOSSIER development and submission

PARTNER is responsible for Market Access & Launch under his brand

Development cost is reduced from 1 M€ to 200- 500 K€ depending on Territorial License

BUSINESS Development TEAM

A REAL COVERAGE



Hafid Touam
USA/Canada



Frederic Besancon
Global/EU



María Teresa Mayo
Global/EU



Hugues Benevent
Global/EU



Ann Donegan
Global/EU



Guillaume Herrier
France



Bruno Schauenberg
LATAM



Amit Patil
Global/MENA/ASIA



Bernadette Matthews
ASIA Junior



Fateh Khan
Africa Junior

CANADA/USA
GLOBAL/EU

BUSINESS DEVELOPMENT TEAM

hafid@tradepassrx.com
frederic.besancon@athenaips.com
hugues.benevent@athenaips.co
mayte.mayo@axelishealthcare.com
guillaume.herrier@athenaips.com
schauenberg.bruno@ddsathena.com
patil.amit@ddsathena.com
matthews.bernadette@ddsathena.com
khan.fateh@ddsathena.com

FRANCE
LATAM
MenaAsia
ASIA
AFRICA

LEAD DOSSIERS FOR LICENSING



ATHENA
PHARMACEUTIQUES

CARDIO AND METABOLISM

- Bisoprolol Aspirin 5 -10/75-100 mg Capsule - **EU**
- Fenofibrate 160/200/267 mg Tablet & Capsule - **EU**

PAIN

- Paracetamol Tramadol 325/37.5 mg Tablet & ODT - **EU/Brazil**

RESPIRATORY

- Levocetirizine 5 mg ODT - **EU/RUSSIA/Brazil**

CENTRAL NERVOUS SYSTEM

- Etifoxine 50 mg Capsule - **EU**
- Ondansetron HCL/Base 4,8 mg ODT - **EU/Canada/Brazil**
- Zolpidem 5,10 mg ODT & SL - **Canada/Brazil/UE**

GASTRO INTESTINAL

- Esomeprazole 20, 40 mg Capsule - **EU**
- Mesalazine 1 g, 2 g Sachet - **EU**
- Racetadotril 10, 30 mg Taste Masked Sachet - **EU**

UROLOGY/ GYNECOLOGY

- Secnidazole 2 g Taste Masked pellets Sachet - **EU**
- Metronidazole 500 mg Tablet - **EU**

Facilities are located in INDIA (Mumbai) and FRANCE (Valenciennes) with state-of-the-art equipment for Solid oral dosage forms
R&D = 50 people



- **Orally disintegrating tablet**
 - Melts rapidly in mouth
 - Taste-Masked & Flavoured
 - No water needed
 - Anytime & Anywhere concept



- **SR/EC/SL Tablets**
Customized drug release technology
 - Modified release Tablet
 - Pellets in Capsules/Sachets
 - Sublingual
 - Trans mucosal



- **SR/EC Pellets in Capsules/Sachets**



- **Effervescent line**
 - Tablets in tube
 - Sticks

Bisoprolol & Aspirin

5/75 mg and 10/75 mg, 5/100 mg and 10/100 mg
Capsule

CARDIO METABOLIC



Fixed combination of two reference agents improving compliance and adherence by 44% to the treatment in the secondary prevention of cardiovascular disease (CVD).



► COMPETITIVE ADVANTAGES

- 78.7% of patients preferred the FDC treatment¹
- 98.3% of patients rated « Excellent » or « Good » Compliance¹
- The original patented formulation⁹ provides an aspirin peak concentration (2h) in advance of bisoprolol peak concentration (4h)
- Aspirin maintenance dose in line with current guidelines : 75-100 mg (ESC 2020; ACC/ AHA 2019)

1. Daily clinical practice Study trial : Compliance and acceptance of a FDC Bisoprolol /Aspirin 5-10/75 mg 356 patients with essential hypertension and/or ischemic heart disease who had been on a free combination of bisoprolol and ASA switched to the FDC formulation

Switch to FDC at least 4 weeks prior inclusion

Study duration : 3 months



► MARKET HIGHLIGHTS

- 17.9 million people died from CVD in 2019
- CVD represents 32% of all global deaths
- 85% of all CVD deaths are due to heart attacks and stroke

► PRODUCT INFORMATIONS

- Bioequivalence - Bisoprolol 10 / Aspirin 75mg strength vs EMCOR® (Merck UK) 10mg and HJERTEMAGNYL® 75mg (Nycomed Denmark).
- Zone IVb Stability data: available
- eCTD dossier available
- Patent submitted and obtained in Europe
- Commercial Batch size (million doses): 0.25 – 1.0 & 2.0
- Shelf-life: 60 months
- Storage conditions: Room temperature below 25°C
- Pack info: 30 size 1 caps Aclar/ aluminium PVC (child resistant)
- Capsule weight: 5/75 mg & 10/75 mg : 326 mg – 5/100 mg and 10/100 mg : 355 mg



Etifoxine

50 mg
Capsule

CNS





Non-benzodiazepine anxiolytic medication with minimal abuse and misuse potential vs. benzodiazepine drugs.

► COMPETITIVE ADVANTAGES

- Anxiolytic effect equivalent to lorazepam, a higher responder rate, and a lower rate of rebound anxiety at treatment discontinuation (one week) in patients receiving etifoxine.

► MARKET HIGHLIGHTS

- Adjustment disorder has been reported to be almost three times as common as major depression (13.7% vs. 5.1%) in acutely ill medical in-patients.
- The Global anxiety disorder and depression treatment market is forecasted to reach \$18.9 Biby 2026 (CAGR of 2.4%).
- Anxiety disorder treatment market is expected to reach \$16.7 M at a CAGR of 5.4% by 20258.



► PRODUCT INFORMATIONS

- Reference compound: STRESAM®, Biocodex
- BioEq. Study referenced EIN-P3-750
 - Patient population: 40 fasting healthy volunteers.
 - Methodology: Monocentric randomized blinded single dose 2-periods, 2-sequences crossover
- Zone IVb Stability data: starting in Q2 2021.
- eCTD dossier.
- Commercial Batch size (million doses): 1.0
- Dossier Batch size (million doses): 1.0
- Shelf-life: 3 years
- Storage conditions: Do not store above 25°C.
- Pack info: PVC (250 µm)/ PVDC (90g/ m²) Alu. (25 µm) blister pack of 15 capsules (box of 60 capsules)
- Capsule weight: 263 mg

Ketorolac Tromethamine

10 mg

Sublingual tablets


PAIN



A sublingual with better and quicker absorption than IM or oral tablet for the short treatment of severe pain in adults.


► COMPETITIVE ADVANTAGES

- Ketorolac is a potent Non-Steroidal Anti-Inflammatory drug widely used in the treatment of moderate to severe pain. Thanks to its sublingual formulation, Athena ketorolac sublingual tablet is more rapidly absorbed vs. conventional oral or IM routes of administration.



► MARKET HIGHLIGHTS

- The global Analgesics market is valued at \$21.2 billion in 2020 is expected to reach \$23.0 billion by the end of 2026 (CAGR 1.1%)



► PRODUCT INFORMATIONS

- Zone IVb Stability data: available
- eCTD dossier available (ANVISA, Brazil format)
- Reference product Toragesic® Brazil
- Commercial Batch size (million doses): 0.750
- Dossier Batch size (million doses): 0.750
- Shelf-life: 24 months
- Storage conditions: Room temperature between 15 and 30°C
- Protect from light and moisture
- Pack info: Amber colored PVC/ PVDC Aluminum blister
- Tablet weight: 80.0 mg

Mesalamine

500 / 1000 & 2000mg Sustained-Release Sachet

GASTROENTEROLOGY




High dosage improves patient's compliance and treatment acceptability

► COMPETITIVE ADVANTAGES

- Athena's Mesalamine (or Mesalazine) sachet formulation offers the same release as conventional Mesalamine tablet preparations with the advantage of fewer oral doses and ease of swallowing¹ and therefore leading to an improved patient's compliance and acceptability of the treatment.
- Excellent First-line therapy for a step-up approach in the management of mild to moderate active ulcerative colitis (UC) and for the maintenance of remission. Mesalamine induces UC remission in 20-30% and UC improvement or remission in 40-70%.
- Mesalamine sachet formulations are more acceptable than tablets for patients and are a better option for long-term treatment.

► MARKET HIGHLIGHTS

- In the US, about 1 million of people are affected with UC.
- Annual incidence is 10.4-12 cases / 100,000 people.
- The global Ulcerative Colitis market accounted for \$6.8 billion in 2018 and is expected to reach \$10.3 billion by 2027 (CAGR of 4.6%).
- Mesalamine market size is \$134.6 million and expected to reach \$181.6 million by 2026 (CAGR of 4.1%).



► PRODUCT INFORMATIONS

- Comparative dissolution study
 - Athena Mesalamine sachet, 1 000 & 2 000 mg vs. reference product (PENTASA® 2 000 mg).
 - Study conditions: Dissolution conducted in a phosphate solution buffered at pH 7.5.
- Zone IV stability data available.
- CTD dossier available.
- All strengths already marketed.
- Patent process (PCT/IN2015 / 000143) filed in EU & China (under review).
- Commercial batch size (million doses) / strength: 500 mg: 0.36 | 1 000 mg: 0.18 | 2 000 mg: 0.09
- Dossier Batch size (million doses) / strength: 1 000 mg: 0.18 | 2 000 mg: 0.09
- Shelf-life: 2 years
- Storage conditions: Room temperature between 20-25°C
- Pack info: Paper coated aluminium sachet
- Sachet weight / strength: 500 mg: 833.4 mg | 1 000 mg: 1 666.7 mg | 2 000 mg: 3 333.3 mg

Metopimazine

7.5 mg

Orodispersible Tablet

ANTIEMETIC



Innovative Orodispersible technology facilitating oral intake

► COMPETITIVE ADVANTAGES


- Firstline treatment of nausea and vomiting
- Orodispersible tablet formulation facilitating water-free intake by oral route in patients suffering from nausea and vomiting or who have difficulties in swallowing
- the use of metopimazine is possible in pregnant women, including during the 1st trimester but not recommended during breast feeding
- Metopimazine is an alternative to Ondansetron that is better tolerated for the prevention of delayed emesis in patients receiving chemotherapy

► MARKET HIGHLIGHTS

- The global nausea and vomiting treatment market size is projected to reach \$7,214 million by 2026 from \$4,947 in 2020 at a CAGR of 6.5% from 2021 to 2026
- The global chemotherapy-induced nausea and vomiting market is valued \$1,663 million in 2015 to reach \$2,659 million by 2022 at a CAGR of 7.1% from 2016 to 2022. According to the US National Cancer Institute chemotherapy-induced nausea and vomiting occurs in up to 80% of patients.

► PRODUCT INFORMATIONS

- CTD Dossier Ready
- Reference product Vogalène® France
- Commercial batch size (doses): 300 000 and 900 000
- Dossier Batch size (doses): 300 000
- Shelf-life (months): 30 months
- Storage conditions: None
- Pack info: Complex PCV/PVDC/Aluminium Blisters
- Tablet weight: 500 mg



Racecadotril

10 & 30 mg

sachet

GASTROENTEROLOGY



Safe and effective product can be given to infants aged over 3 months

→ COMPETITIVE ADVANTAGES


- Racecadotril is a guideline-recommended treatment to alleviate symptoms of acute diarrhoea. Safety profile is similar to that of placebo. Racecadotril inhibits the degradation of enkephalins, which in turn have potent antisecretory activity but only little effect on motility in the gut in contrast to loperamide (IMODIUM®).
- Resolution of symptoms with racecadotril when compared to loperamide is associated with less rebound constipation and less abdominal discomfort.
- Superior acceptability of Athena formulation vs. reference (TIORFAN®) regarding bitterness, mouth feeling and flavour.
- Racecadotril is indicated for the complementary symptomatic treatment of acute diarrhoea in infants aged over 3 months.

→ MARKET HIGHLIGHTS

- Worldwide, 1.7 billion episodes of Acute Secretory Diarrhoea occur each year.
- Children's diarrhoea drug treatment account for the largest market share (63% in 2019).
- Global antidiarrheal Drugs market is valued \$4,3 billion reaching \$5.8 billion by 2026 (CAGR: 4.5%).

→ PRODUCT INFORMATIONS

- Reference compound: TIORFAN®, Bioprojet Pharma.
- BioEq. study
 - Patient population: 48 male and female fasting healthy volunteers.
 - Methodology: Randomized single-dose 2-way crossover (Test and reference administered with water).
 - Reference product: TIORFAN®, Bioprojet Pharma, France.
- Zone II & IV stability data available.
- CTD dossier available.
- Patent filed in USA, EU, Brazil, Mexico, Russia, China & Korea Regarding the pharmaceutical composition & process for preparation of racecadotril (PCT/IN2018/050085).
- Commercial batch size (thousand doses) / strength: 10 mg: 330 | 30 mg: 110
- Dossier Batch size (thousand doses) / strength: 10 mg: 330 | 3 mg: 110
- Shelf-life: 3 years
- Storage conditions: Room temperature between 20-25°C
- Pack info: Heat sealed aluminium sachet. A soft tempered, silver coloured, one side shiny and other side opaque, printed alu. foil
- Sachet weight / strength: 10 mg: 1 000 mg | 30 mg: 3 000 mg



Secnidazole

2 mg
sachet

GYNÄCOLOGY



First oral single-dose treatment for bacterial vaginosis

► COMPETITIVE ADVANTAGES


- Next-generation 5-nitroimidazole prodrug granted priority review by the FDA with longer half-life (17h) allowing for a once-daily dosing.
- Secnidazole has similar activity against the range of microorganisms associated with bacterial vaginosis compared to metronidazole or tinidazole whilst sparing Lactobacilli, beneficial microorganisms.
- Single-dose oral treatment of bacterial vaginosis vs. oral metronidazole twice a day for seven days, or tinidazole or clindamycin for two to seven days.
- No significant drug-drug interaction with oral contraceptives containing ethinyl oestradiol & norethindrone.
- Administration can occur without regard to the timing of meals.

► MARKET HIGHLIGHTS

- 84% of women suffering from bacterial vaginosis have no symptoms (CDC).
- Prevalence of bacterial vaginosis is estimated to be 29,2% in women aged 14-49 (21.1M) (CDC).
- Global Bacterial Vaginosis Drug market is valued at \$800 million in 2018 and will reach \$1.03 billion by 2025 (CAGR 2019-25: 3.2%)⁴.

► PRODUCT INFORMATIONS

- BioEq. study
 - Patient population: 30 male & female healthy volunteers.
 - Methodology: Randomized 2-way crossover single dose study.
 - Reference product: SECNOL® 2 g sachet Iprad, France.
- Zone IV stability data available.
- CTD dossier available.
- Commercial batch size (thousand doses): 65
- Dossier Batch size (thousand doses): 65
- Shelf-life: 2 years
- Storage conditions: Room temperature between 20-25°C
- Pack info: Pellets in self-sealed polyethylene bag and finished pack in paper alu. coated sachet
vSachet weight / strength: 4 228 mg



Tranexamic Acid

1g

Taste Masked Pellets Sachet

GYNÄCOLOGY



An improved and reduce intake of a best in a class drug for haemorrhagic conditions

► COMPETITIVE ADVANTAGES


- Tranexamic acid is useful in a wide range of haemorrhagic conditions.
- Tranexamic acid reduces menstrual blood loss and is a possible alternative to surgery in menorrhagia and has been used successfully to control bleeding in pregnancy.
- The drug reduces postoperative blood losses and transfusion requirements in several types of surgery, with potential cost and tolerability advantages over aprotinin, and appears to reduce rates of mortality and urgent surgery in patients with upper gastrointestinal haemorrhage.
- The FDA-approved usage for tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with haemophilia; this includes tooth extractions in patients with haemophilia as well as menorrhagia in these patients.
- Tranexamic acid works by slowing the breakdown of blood clots, which helps to prevent prolonged bleeding. It does not treat other menstrual or pre-menstrual symptoms. It does not stop your period.

► MARKET HIGHLIGHTS

- Global Tranexamic Acid Market is expected to gain market growth in the forecast period of 2022 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.80% in the above-mentioned forecast period.

► PRODUCT INFORMATIONS

- Zone IVb stability: Study ongoing
- E-CTD dossier : Available
- Reference product CYKLO-F® 500 mg
- Commercial batch size – 225 kg equivalent to 125 000 sachets of 1g
- Dossier Batch size – 125 000 sachets
- Shelf-life – 2 years – 3 years under Stability
- Storage conditions – store at room temp. at 15°C – 30 °C
- Pack Info: Aluminium sachet
- Sachet weight / strength: for 1 g – 1750 mg



Zolpidem

5 & 10 mg

Sublingual tablet

CNS



Faster sleep onset initiation and lesss variability versus conventional tablet

► COMPETITIVE ADVANTAGES


- Faster and less variability sleep initiation in patients suffering from insomnia compared to conventional tablet formulations.

► MARKET HIGHLIGHTS

- Insomnia is one of the largest CNS disorders, affecting on average one adult out of 3.
- Global insomnia market valued at \$4.1 billion in 2016 and estimated to reach \$5.5 billion by 2023 at a CAGR of 4.2% from 2017 to 2023.

► PRODUCT INFORMATIONS

- Reference compound: SUBLINOX®, Valeant.
- BioEq. study
 - Patient population: 27 Healthy Volunteers.
 - Methodology: Randomized 2-way crossover study, single dose (test & reference without water).
- Reference product: SUBLINOX® tablets, Valeant Canada.
- Zone IV stability data available.
- CTD dossier available.
- Commercial batch size (million doses) / strength: 5 mg: 1.0 | 10 mg:0.5
- Dossier Batch size (million doses) / strength: 5 mg: 0.2 | 10 mg:0.125
- Shelf-life: 36 months
- Storage conditions: Store in cool dry conditions in well-sealed receptacles
- Transport conditions: None
- Pack info: 5 & 10 mg - 10-tabs Alu-Alu blister, 10 blister strips packed/ carton
- Tablet weight / strength: 5 mg: 150 mg | 10 mg: 300 mg
- Flavour: Blackcurrant



WORLDWIDE ACCREDITATIONS



ATHENA
PHARMACEUTIQUES

HEALTH AUTHORITIES



EMA - EU



HEALTHCANADA - Canada



ANVISA - Brazil



SAHPRA - South Africa



Ministry of Health of the Russian Federation - Russia



Taiwan FDA - Taiwan



Ministry of Food and Drug Safety - Korea



TGA - Australia



DIGEMID - Peru



FDA - Philippines



MCA - Zimbabwe



DCGI CDSCO - India



ATHENA DDSINDIA



ATHENA IPS FRANCE



CTD PRODUCTS LIST



MOLECULE	STRENGTH	DOSAGE FORM	REFERENCE	ATHENA India	ATHENA France
ALLERGY					
Levocetirizine	5 mg	Oro-Dispersible Tablet	Xyzall® UCB France, Brazil, Russia	Ready	Q3 2022
ANTI- EMETIC / ONCOLOGY					
Domperidone	10 mg	Oro-Dispersible Tablet	Motilim Instant® ODT Janssen Belgium	Ready	
Ondansetron	4 & 8 mg	Oro-Dispersible Tablet	Zofren® ODT GSK UK, GSK Canada	Ready	
Ondansetron HCL	4 & 8 mg	Oro-Dispersible Tablet	Vonau Flash® Biolab Brazil	Ready	
CARDIO METABOLIC					
Bisoprolol Aspirin	5-10 &75-100mg	Capsule	Emcor® Merck /Aspirin Nycomed	Ready	
Fenofibrate	67 /200/267 mg	Capsule/ Tablet	Lipanthyl® Abbott France /UK	Ready	
Metformin	750 mg	Sustained Release Tablet	Glucophage XR® Merck Serono UK	Ready	
CNS					
Donepezil	5 & 10 mg	Oro-Dispersible Tablet	Eranz® Tablet Wyeth Brazil	Ready	
Etifoxine	50 mg	Capsule	Stresam® Biocodex France	Ready	
Hydroxyzine	25 mg	Film Coated Tablet	Atarax® UCB France		Q4 2022
Zolpidem	5 & 10 mg	Oro-Dispersible Tablet	Stilnox® Sanofi France	Ready	
Zolpidem	5 & 10 mg	Sublingual Tablet	Sublinox® Valeant Canada, Patz®Brazil	Ready	
DENTAL					
Spiramycine + Metronidazole	0.75 /1.5 MUI + 125/250 mg	Film Coated Tablet	Rodogyl® Sanofi		Q4 2022
GASTROENTEROLOGY					
Esomeprazole	20 & 40 mg	Enteric Coated Capsule	Inexium® Tablet AstraZeneca France	Ready	Q2 2022
Mesalamine	1 & 2 gms	Sustained Release pellets Sachet	Pentasa® 2 gms Ferring France	Ready	
Metronidazole	250 & 500 mg	Film Coated Tablet	Flagyl® Sanofi France		Q3 2022
Raceca dotril	10 & 30 mg	Taste Masked Granules Sachet	Tiorfan® Bioprojet France Hydrasec® Abbott	Ready	Q3 2022

CTD PRODUCTS LIST



MOLECULE	STRENGTH	DOSAGE FORM	REFERENCE	ATHENA India	ATHENA France
GYNECOLOGY					
Secnidazole	2 g	Taste Masked pellets Sachet	Secnol® Iprad France	Ready	Q3 2022
Sildenafil	50 & 100 mg	Oro-Dispersible Tablet	Viagra® Pfizer Russia	Ready	
OTC					
Cetylpyridium + lysozyme	1.5 + 20 mg	Tablet	Lysopaine® Sanofi	Q2 2022	
ORPHAN / HYPONATREMIA SIADH					
Demeclocycline	150 mg	Capsule	Alkonatrem® Primius	Ready	
PAIN / ANTI-INFLAMMATORY					
Ibuprofen	200 & 400 mg	Oro-Dispersible Tablet	Brufen® Tablets Mylan France	Ready	
Ketoprofen + Omeprazole	200 mg + 20 mg	Pellets in Capsule	Profenid® Protect 200 /20 mg Sanofi Brazil	Q4 2021	
Ketorolac Trometamol	10 mg	Sublingual Tablet	Toragesic® EMS Brazil	Ready	
Meloxicam	7.5 & 15 mg	Oro-Dispersible Tablet	Mobic® Boehringer Ingelheim France	Ready	
Paracetamol	500 mg, 1 gm	Effervescent Tablet		Q1 2022	
Prednisolone	5 & 10 mg	Soluble Tablet	Prednesol Tablets 5mg, Concordia UK	Ready	
Prednisolone	1 & 5 mg	Oro-Dispersible Tablet	Prednesol Tablets 5mg, Concordia UK	Q4 2021	
Tramadol + Paracetamol	37.5 + 325 mg	Tablet	Tramacet® Janssen Cilag UK	Ready	
Tramadol + Paracetamol	37.5 + 325 mg	Oro-Dispersible Tablet	Zaldiar® Brunenthal Germany	Ready	

OUR PARTNERS...



EUROPE
CANADA



ASIA
INDIA



MIDDLE
EAST
AFRICA



LATAM

CONTACT US



FRANCE OFFICE

•ATHENA Pharmaceutique s SAS
Bat D6, étage Bureaux de la colline 92210
St. Cloud,
FRANCE

FRANCE FACTORY

•ATHENA IPS
1 Rue de Nungesser 59121 Prouvy,
FRANCE
Tel: +33327434500

INDIA OFFICE

•ATHENA Drug Delivery Solution Pvt Ltd
602, Star Hub, Tower II, Sahar International
Airport Road, Andheri East, Mumbai 400 099,
INDIA
Tel: +91 22 6737 0700

INDIA FACTORY R&D CENTER

•Athena Drug Delivery Solutions Pvt Ltd
Plot No. A1-A5, M.I.D.C., Chembur Zone, Near
Ion Exchange, Ambernath West - 421 501, INDIA
Tel: +91 744 7461 662/3/4/5, +91 960 794 8231/2/3/4

CHINA OFFICE

•Athena-JSI Pharmatech (Shanghai) Ltd.
Suite 302, Building 6A, 590 Ruiqing Road,
Pudong District, Shanghai 201 201,
CHINA

CANADA & USA

•Athena Canada Inc.
64 Jardin Drive, Suite 1 C
Vaughan ON L4K 3P3 CANADA
Hafid Touam
Tel: +1(267) 358-6250
Cell : +1(484) 832-0404

BRAZIL OFFICE

•Athena Brasil Consultoria Farmaceutica Eireli
New Century Building
11th Floor, Leopoldo Couto de Magalhaes,
Junior Str. 758 Itaim Bibi, Sao Paulo 04542-000
BRAZIL
Tel: +55 11 96645 1184

BUSINESS DEVELOPMENT TEAM

•AFRICA: khan.fateh@ddsathena.com
•ASIA: matthews.bernadette@ddsathena.com
•CANADA/USA : hafid@tradepassrx.com
•FRANCE : guillaume.herrier@athenaips.com
•GLOBAL/EU : frederic.besancon@athenaips.com
•LATAM : hugues.benevent@athenaips.com
•MENA : schauenberg.bruno@ddsathena.com
patil.amit@ddsathena.com

We are EUGMP - ANVISA - CANADA - RUSSIA - SOUTH AFRICA
- AUSTRALIA - TAIWAN - KOREA approved facility

ATHENA has a team of 400 people specialised in development and manufacturing Oral Solid Drug Delivery Products.